Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00750399 · ClinicalTrials.gov registry record · Phase 1
Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma
A Phase 1 study, sponsored by The New York Eye Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00750399 is a Phase 1 study that has completed, run by The New York Eye Cancer Center. The registered enrollment target is 10 participants.
The verdict
NCT00750399, a Phase 1 study, has completed, sponsored by The New York Eye Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a Phase I clinical trial to test the safety and tolerability of intravitreal ranibizumab in the treatment of radiation retinopathy following plaque brachytherapy for patients with choroidal melanoma using the incidence and severity of events criteria. The secondary objective is to assess the efficacy of intravitreal ranibizumab on regression of radiation retinopathy by ophthalmic examination, fundus photography, fluorescein angiography, and optical coherence tomography, as well as visual acuity.
Interventions
- DRUG Ranibizumab
- DRUG ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00750399
The ClinicalTrials.gov registry entry for NCT00750399 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The New York Eye Cancer Center, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ranibizumab is the first listed.
NCT00750399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00750399 about?
NCT00750399 is a clinical study titled "Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma". This is a Phase I clinical trial to test the safety and tolerability of intravitreal ranibizumab in the treatment of radiation retinopathy following plaque brachytherapy for patients with choroidal melanoma using the incidence and severity of events criteria. The secondary objective is to assess th...
What is the current status of trial NCT00750399?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2008-10. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00750399?
The interventions under investigation include: Ranibizumab (DRUG), ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00750399?
This trial is sponsored by The New York Eye Cancer Center, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.